Strategy’s second quarter results reflected a stable revenue environment, meeting Wall Street’s top-line expectations despite a significant shortfall on GAAP earnings per share. Management highlighted robust deal flow and continued strength in both the life sciences and technology verticals as core contributors to growth. CEO Scott Bluestein attributed the performance to “record originations” and disciplined underwriting, noting that 59% of new commitments targeted life sciences while funding remained diversified. The company also emphasized the role of early loan repayments, driven by M&A activity and fresh equity rounds among portfolio companies.
Is now the time to buy MSTR? Find out in our full research report (it’s free for active Edge members).
Strategy (MSTR) Q2 CY2026 Highlights:
- Revenue: $122.4 million vs analyst estimates of $122.1 million (6.9% year-on-year growth, in line)
- EPS (GAAP): -$24.45 vs analyst estimates of $3.07 (significant miss)
- Billings: $112 million at quarter end, down 1.1% year on year
- Market Capitalization: $37.8 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Strategy’s Q2 Earnings Call
- Crispin Love (Piper Sandler) asked about the outlook for capital deployment and seasonality; President Seth Meyer confirmed Q3 is typically slower but expects robust activity and strong deal screening.
- Finian O'Shea (Wells Fargo Securities) questioned growth strategy and private credit fund scaling; CEO Scott Bluestein said growth would come from both BDC and private funds, with no plans for strategy drift and a continued focus on market specialization.
- Chris Muller (Citizens JMP Securities) probed AI’s dominance in venture deals and potential opportunities beyond AI; Bluestein explained that while AI is prominent, non-AI sectors remain robust and diversification remains a priority.
- Christopher Nolan (Ladenburg Thalmann) inquired about competition from banks and AI data governance; Bluestein noted banks are aggressive but cyclical, while Meyer detailed strict controls on AI data usage and governance.
- Melissa Weddle (UBS) asked about portfolio companies’ fundraising strength and its impact on debt origination; Bluestein explained robust equity raises support, rather than compete with, increased venture debt activity.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will watch (1) the pace of new originations and ability to redeploy capital after elevated prepayments, (2) the sustainability of strong fundraising and M&A activity among portfolio companies, and (3) the impact of increased competition from banks and non-bank lenders on underwriting discipline and credit quality. Advances in technology infrastructure and AI governance will also be important markers of operational scalability.
Strategy currently trades at $97.75, in line with $97.74 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
